Libeksin tab 100mg 20 pieces

Description

Composition
Active substance:
1 tablet contains: prenoxdiazine hydrochloride – 100 mg.
Excipients:
Glycerol (glycerin), magnesium stearate, talc, povidone, corn starch, lactose monohydrate.
Description:
Round flat tablets white or almost white color with a facet on both sides. On one side is engraved «LIBEXIN», on the other side – the risk of dividing the tablet into four parts.
Product form:
Tablets of 100 mg. 20 tablets in a blister from a film of aluminum foil and polyvinylchloride. 1 blister together with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to the drug. Diseases associated with abundant bronchial secretion. Condition after inhalation anesthesia. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Precautions: children’s age.
Dosage
100 mg
Indications
Nonproductive cough of any origin (for catarrh of the upper respiratory tract, influenza, acute and chronic bronchitis, pneumonia, emphysema, nocturnal cough in patients with heart failure; preparation to patients or bronhograficheskomu bronchoscopic investigation).
Interaction with other drugs
It is not recommended to combine the drug with mucolytic and expectorant agents, as it can impede sputum, deflocculating latter. There is no preclinical or clinical data on the interaction with other drugs.
Overdose
overdose data are available for humans. In case of receiving the dose exceeding the therapeutic one, may develop weakness and sedation.
pharmachologic effect
Pharmacological group:
Peripheral antitussive action.
Pharmacodynamics:
Prenoxdiazine is a peripheral antitussive action. The drug blocks the peripheral units cough reflex due to the following effects: local anesthetic effect, which reduces the excitability of peripheral sensory (cough) respiratory tract receptors; bronchodilator action, whereby a suppression of stretch receptors involved in the cough reflex; a slight decrease in activity of the respiratory center (without respiratory depression). Antitussive effect of the drug is approximately equal to that of codeine. Prenoxdiazine does not cause addiction and drug dependence. In chronic bronchitis prenoxdiazine marked anti-inflammatory effect. Prenoxdiazine does not affect the central nervous system function, except for the possible indirect anxiolytic effect.
Pharmacokinetics:
Prenoxdiazine quickly and largely absorbed from the gastrointestinal tract. Maximum plasma concentration achieved prenoxdiazine 30 minutes after taking the drug, its therapeutic concentration is maintained for 6-8 hours. Communication plasma protein is 55-59%. half-life is 2.6 hours. Most of the dose is metabolized in the liver is only about 1/3 the dose of the drug is excreted unchanged, and the rest – in the form of metabolites (metabolite allocated prenoxdiazine 4). During the first 12 hours metabolism prenoxdiazine most important role is played by biliary excretion and its metabolites. After 24 hours, after ingestion is allocated 93% of the formulation. 72 hours after ingestion of 50-74% of the dose is excreted in the feces and 26-50% – in the urine.
Pregnancy and breast-feeding
During pregnancy and lactation, the use Libeksina® possible only if the potential benefit to the mother outweighs the potential risk to the fetus or child.
Conditions of supply of pharmacies
Without recipe.
side effects
allergic reactions
Rare: skin rash, angioedema.
Unknown frequency: bronchospasm.
On the part of the gastrointestinal tract
Rare: dry mouth and throat, anesthesia (temporary numbness and loss of sensitivity) of the oral mucosa.
Less than 10% of the cases: stomach pain, tendency to constipation, nausea.
From the nervous system (using a preparation in high doses): light sedation, tiredness. It should be emphasized that, as sedation and fatigue, are shown at higher therapeutic doses, and all the symptoms cease spontaneously within a few hours after discontinuation.
special instructions
The drug can cause complaints from the gastrointestinal tract in patients with lactose intolerance, because tablets contain lactose (0.38 mg of lactose in each tablet)
The effect on the ability to drive vehicles and perform tasks associated with increased risk
Acceptance of the drug in high doses, can slow down the speed of reactions, so while taking the drug in high doses, the issue of driving ability or busy with work associated with increased risk, should be decided individually.
Storage conditions
Store at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
The average dose for adults is 100 mg three or four times a day (1 tablet 3-4 times a day). In more complex cases the dose may be increased up to 200 mg three – four times or 300 mg three times a day (2 tablets 3-4 times daily or 3 tablets 3 times a day). The average dose for children, depending on age and body weight of 25-50 mg three or four times a day (1/4 – 1/2 tablet 3-4 times a day). The maximum single dose for children – 50 mg (half tablets), adult – 300 mg (3 tablets). The maximum daily dose for children – 200 mg (2 tablets) for adult – 900 mg (9 tablets). In preparation for bronchoscopy dose of 0.9 – 3.8 mg / kg of body weight is combined with 0.5 – 1 mg atropine for 1 hour before the procedure. Tablets are swallowed without chewing (to avoid oral mucosal anesthesia).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist